Saudi Central Bank Increases Stakes
Saudi Central Bank increases holdings in major companies including Pfizer and AT&T.
Anonymous
Key Points
1
Union Pacific is heavily institutionally owned, with institutional investors and hedge funds holding 80.38% of its outstanding shares.
2
Analysts raised Union Pacific’s targets significantly: TD Cowen increased its price target from $282 to $325, while Bank of America raised its target from $301 to $334; both maintained buy ratings.
3
Wells Fargo’s institutional ownership stands at 75.90%, with major recent purchases including new positions by Norges Bank, Legal & General Group, Bank of New York Mellon and Deutsche Bank.
4
Pfizer received FDA approval for the 2026–2027 COMIRNATY XFG COVID-19 vaccine formulation for high-risk age groups and launched a Phase 3 Japanese study of berobenatide, an obesity-drug candidate.
5
AT&T’s analyst views were mixed: Morgan Stanley raised its price target to $27 and assigned an overweight rating, while Wells Fargo raised its target to $20 but retained an underweight rating; Goldman Sachs set a $30 target.
Saudi Arabia's central bank is doubling down on major U.S. stocks, expanding positions in Pfizer, Union Pacific, Wells Fargo, and AT&T during the second quarter. Watchlist News reported the bank increased its Pfizer stake 23.9% to 976,902 shares worth $24.1 million, while its Union Pacific position jumped 89.8% to 41,558 shares valued at $11.3 million. The moves signal continued confidence in these blue-chip companies, even as some face mixed analyst outlooks.
The Saudi Central Bank also boosted Wells Fargo holdings 85.1% to 214,501 shares worth $17.7 million and raised its AT&T position 13.9% to 1.86 million shares valued at $40.3 million. These increases reflect institutional appetite for dividend-paying stocks and established industrial names amid broader market uncertainty.
Union Pacific Draws Big Bets From Wall Street
Union Pacific is a magnet for institutional money. Ticker Report noted that 80.38% of the railroad's shares are held by institutional investors and hedge funds. Two major analysts recently raised price targets on the stock, signaling bullish momentum. Ticker Report reported TD Cowen lifted its target from $282 to $325 and maintained a buy rating, while Bank of America raised its target from $301 to $334, also keeping its buy rating.
Wells Fargo Attracts Wave of New Institutional Buyers
Wells Fargo's recent moves show heavy institutional interest. Watchlist News reported the bank's institutional ownership sits at 75.90%, with major new positions added by Norges Bank, Legal & General Group, Bank of New York Mellon, and Deutsche Bank. These large purchases suggest confidence in the bank's turnaround strategy and earnings recovery potential.
Pfizer Advances Vaccine and Obesity Drug Programs
Pfizer's pipeline is strengthening. Watchlist News reported the company won FDA approval for its 2026–2027 COMIRNATY XFG COVID-19 vaccine formulation for high-risk age groups. The pharma giant also launched a Phase 3 Japanese study of berobenatide, an obesity-drug candidate. These regulatory wins and pipeline progress underpin the Saudi Central Bank's increased confidence in the stock.
AT&T Faces Divided Analyst Views on Valuation
AT&T's outlook remains mixed among Wall Street analysts. Ticker Report reported Morgan Stanley set a $27 price target with an overweight rating, while Goldman Sachs assigned a $30 target. However, Wells Fargo raised its target to $20 but kept an underweight rating, citing valuation concerns. The Saudi Central Bank's modest 13.9% increase suggests cautious optimism amid this analyst disagreement.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
15
Articles
13
Reach
28
A
AnonymousAuthor
